Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Bone grafting material, dental, with biologic component

PMA Number: P040013 · 2026-08-03

ApplicantLynch Biologics, LLC
Decision Date2026-08-03
PMA NumberP040013
Product CodeNPZ
Device ClassClass 3
Medical SpecialtyD
Regulation Number21 CFR 8
Advisory CommitteeDE

Device Summary

Bone grafting material, dental, with biologic component is the device name listed in this FDA 510(k) record. The listed applicant is Lynch Biologics, LLC. It received FDA 510(k) clearance on 2026-08-03. The device is classified under product code NPZ. It was reviewed by the DE advisory panel.

Frequently Asked Questions

What is the Bone grafting material, dental, with biologic component?

Bone grafting material, dental, with biologic component is a medical device that received FDA 510(k) clearance on 2026-08-03. The listed applicant is Lynch Biologics, LLC.

When did Bone grafting material, dental, with biologic component receive FDA 510(k) clearance?

The clearance date for Bone grafting material, dental, with biologic component can be found in the official FDA records.

Who is the listed applicant for Bone grafting material, dental, with biologic component?

The FDA 510(k) record lists Lynch Biologics, LLC as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Bone grafting material, dental, with biologic component?

The FDA product code for Bone grafting material, dental, with biologic component is NPZ.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑